Please login to the form below

Not currently logged in
Email:
Password:

Roche to buy medical scanning company

Roche is to buy California-based medical scanning company BioImagene for $100m, strengthening its position in tissue-based cancer diagnostics

Swiss drugmaker Roche is buying California-based, medical scanning company BioImagene for $100m, adding another bolt-on acquisition to strengthen its dominant position in tissue-based cancer diagnostics.

Diagnostics is gaining more importance in cancer treatment, which is being increasingly dovetailed to the genetic profile of patients. Roche is the world's largest maker of cancer drugs.

Roche says it expects to complete the purchase of privately held BioImagene in the coming weeks.

"As part of the personalised healthcare approach, pathologists are increasingly involved in generating information with high impact on treatment decisions," Daniel O'Day, chief operating officer at Roche Diagnostics said in a statement.

BioImagene's products create high-resolution, whole-slide digital images from glass microscope slides. The privately held group also provides the software to view, analyse and manage tissue images using a computer.

BioImagene differentiates itself by being the only end to end workflow management company with a suite of leading edge products for acquisition through image analysis, to decision support to report.

"We view the bolt-on acquisition as a good complement to the existing offering in tissues diagnostics, which is becoming increasingly important and crucial for personalised therapy options," said Kepler Capital Markets analyst Martin Voegtli.

23rd August 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
Can involving patients in design transform the clinical trial experience?
While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...

Infographics